Your weekly recap of news and analysis from the psychedelic sector.
Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A
This week: MAPS’ phase 3 study is published in Nature Medicine; Numinus announced a number of key hires; CB Therapeutics closes Series A revealing close Atai connections; and more…
Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain; the Proliferation of Deuteration
This week: MAPS’ MDMA for PTSD trial shows strong results; MindMed announces Project Angie, targeting pain indications; Small Pharma set to receive first patent grant; and more…
Psychedelic Bulletin: MindMed Uplists to Nasdaq; Cybin Targets Alcoholism; COMPASS Announces $144m Offering
This week: MindMed’s somewhat lacklustre Nasdaq debut; Cybin announces alcohol use disorder as target indication for CYB003; COMPASS to raise $144m in public offering; and more…
Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon Brands Resumes Trading
This week: Nasdaq is casting a spell on the space as MindMed announces uplisting, and Atai announces IPO; Champignon Brands recommences trading in Canada; and more…
Psychedelic Bulletin: Experts Weigh in on Psilocybin vs. SSRIs; GH Research Closes $125m Round; California Decrim. Bill Passes 2nd Key Committee
This week: With the publication of a long-awaited psilocybin vs. SSRI study, we speak to experts on the topic; GH Research closed their Series B; California inches closer to decrim.; and more…
Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company
This week: California’s decriminalisation bill passed a key committee; MindMed publishes MDMA dosing study; atai acquires brain-computer interface company; and more…